Elaine Cachia1, Sam H Ahmedzai. 1. Academic Unit of Supportive Care, Department of Oncology, School of Medicine and Biomedical Science, Royal Hallamshire Hospital, Sheffield, UK.
Abstract
PURPOSE OF REVIEW: Cancer patients with moderate-to-severe pain require opioids for analgesia. Whereas early guidelines recommend oral morphine as the 'drug of choice', newer synthetic opioids can be given by a reliable and effective nonoral transdermal route. We examine the mode of action of transdermal patches and we review the evidence on two drugs, which are currently available in this formulation - buprenorphine and fentanyl - covering physicochemical characteristics and pharmacokinetics of the patches, clinical efficacy data and adverse effects. RECENT FINDINGS: Both buprenorphine and fentanyl possess ideal characteristics for transdermal delivery, being small molecules with high lipophilicity. Studies of buprenorphine patches show benefits but there is poor randomized controlled trial evidence comparing them with oral opioids. Fentanyl patches have been used for longer and have a larger body of evidence supporting their use, with data to suggest improved pain relief and reduced opioid side effects compared with sustained release oral morphine. Patients who have used both oral morphine and transdermal fentanyl express a preference for the patch drug. SUMMARY: Transdermal buprenorphine and fentanyl are now established for moderate-to-severe cancer pain. There is still a need for further comparative studies with other opioids, especially for buprenorphine.
PURPOSE OF REVIEW: Cancerpatients with moderate-to-severe pain require opioids for analgesia. Whereas early guidelines recommend oral morphine as the 'drug of choice', newer synthetic opioids can be given by a reliable and effective nonoral transdermal route. We examine the mode of action of transdermal patches and we review the evidence on two drugs, which are currently available in this formulation - buprenorphine and fentanyl - covering physicochemical characteristics and pharmacokinetics of the patches, clinical efficacy data and adverse effects. RECENT FINDINGS: Both buprenorphine and fentanyl possess ideal characteristics for transdermal delivery, being small molecules with high lipophilicity. Studies of buprenorphine patches show benefits but there is poor randomized controlled trial evidence comparing them with oral opioids. Fentanyl patches have been used for longer and have a larger body of evidence supporting their use, with data to suggest improved pain relief and reduced opioid side effects compared with sustained release oral morphine. Patients who have used both oral morphine and transdermal fentanyl express a preference for the patch drug. SUMMARY: Transdermal buprenorphine and fentanyl are now established for moderate-to-severe cancer pain. There is still a need for further comparative studies with other opioids, especially for buprenorphine.
Authors: Sheena Derry; Cathy Stannard; Peter Cole; Philip J Wiffen; Roger Knaggs; Dominic Aldington; R Andrew Moore Journal: Cochrane Database Syst Rev Date: 2016-10-11
Authors: Allison J Thiede; Kelly D Garcia; DeAnne F Stolarik; Junli Ma; Gary J Jenkins; Elizabeth A Nunamaker Journal: J Am Assoc Lab Anim Sci Date: 2014-11 Impact factor: 1.232
Authors: Sarah M Gruba; Danielle H Francis; Audrey F Meyer; Eleni Spanolios; Jiayi He; Ben M Meyer; Donghyuk Kim; Kang Xiong-Hang; Christy L Haynes Journal: ACS Meas Sci Au Date: 2021-08-24
Authors: Jin Seok Ahn; Johnson Lin; Setsuro Ogawa; Chen Yuan; Tony O'Brien; Brian Hc Le; Andrea M Bothwell; Hanlim Moon; Yacine Hadjiat; Abhijith Ganapathi Journal: J Pain Res Date: 2017-08-18 Impact factor: 3.133